Transactions

Retains royalty rights to odanacatib and other Celera drug assets. Madison, NJ (US) and New York, NY (US) – July 18, 2013  — Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today that it has completed the sale of its rights to

New York, NY (US) – June 18, 2013  — Royalty Pharma announced today that it had withdrawn its request for a judicial review of the Irish Takeover Panel’s decision requiring it to lapse its offer for Elan Corporation, plc (NYSE: ELN) if, among other things, Elan shareholders approved the Share

Purchase of Interest in Fumapharm Earn-Out Represents Interest in BG-12 and Fumaderm. New York, NY (US) – May 2, 2012  — Royalty Pharma announced today that it had acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash.

Design and Execution of VALOR Trial Enable Innovative Financing. New York, NY (US) and South San Francisco, CA (US) – March 29, 2012  — Royalty Pharma and Sunesis Pharmaceuticals (NASDAQ:SNSS) today announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances

New York, NY (US) – February 29, 2012  — Royalty Pharma announced today that it has acquired certain rights to receive royalties on future worldwide net sales of Cimzia® and Mircera® for an aggregate cash payment of $124 million. Cimzia, marketed by UCB and launched in the United States and the

San Francisco, CA (US) – February 29, 2012  — Nektar Therapeutics (Nasdaq: NKTR) today announced that it agreed to sell to Royalty Pharma its royalties on future sales of CIMZIA®, under Nektar’s agreement with UCB Pharma, and MIRCERA®, under Nektar’s agreement with Roche.

Boston, MA (US) – August 11, 2011  -– Arisaph Pharmaceuticals, Inc. (“Arisaph”) and Royalty Pharma announced today the closing of a transaction valued up to $26.25 million. Under the terms of the amendment, Royalty Pharma has paid Arisaph $17 million in cash and has agreed to pay Arisaph future

Tokyo, Japan – June 30, 2011  — Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) announced today that Prosidion_s patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes has been sold to Royalty Pharma for a

New York, NY (US) – April 4, 2011  — Royalty Pharma announced today that it has acquired the rights to certain royalties payable on sales of Lexiscan® and Cubicin® from an undisclosed seller for a cash payment of $487 million. Lexiscan® (regadenoson) is a market-leading pharmacologic stress agent